While the Buy rating suggests that Jefferies still sees Acelyrin as a good investment, the reduction in the price target could lead to mixed reactions in the short term. Investors may view the lowered target as a sign of tempered expectations, which could result in a neutral impact on the stock price as the positive rating and the negative price target adjustment may offset each other.